Ocena ekspresji receptora estrogenowego, progesteronowego i receptora HER2 w wybranych nowotworach złośliwych ślinianek
Journal Title: Otolaryngologia Polska - Year 2013, Vol 67, Issue 5
Abstract
Introduction: The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor. Aim: The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies. Materials and methods: Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed. Results: The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor – salivary duct carcinoma. Conclusion: HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
Authors and Affiliations
Wojciech Golusiński, Anna Wegner, Paweł Trzeciak, Marcin Sówka, Andrzej Kopczyński, Małgorzata Bromboszcz
Keywords
Related Articles
- EP ID EP52211
- DOI -
- Views 105
- Downloads 0
Ear carcinomas in Department of Otolaryngology of the Medical University of Warsaw in years 2004-2008
SUMMARY Ear carcinoma constitutes 0.5% of all cancers of the head and neck hardly, however with poor prognosis. In the study we use University of Pittsburgh Staging System. This study is retrospective analysis of the sur...
The advanced hypopharyngeal cancers surgery treatment complications
SUMMARY Introduction: Hypopharynx is the anatomical region created by strictly functionally connected regions: two pyriform sinuses, retrocricoid region and the posterior pharyngeal wali on its level. Hypopharyngeal Canc...
Trudności diagnostyczne chorego z guzem masywu szczękowo-sitowego; dylematy terapeutyczne
Mitochondrial DNA mutations in the pathogenesis in the head and neck squamous cell carcinoma
Data reported until today suggested a pivotal role of nuclear DNA mutations in the process of carcinogenesis. Recently more and more authors claim that disruption of mitochondrial DNA should not be excluded from this ana...
Head and neck tuberculosis — stili current problem in ENT practice
SUMMARY Introduction: It is estimated that between XVI and XIX century one fourth of European population died of tuberculosis. Nowadays tuberculosis is stili one of the most important infectious diseases. In 2009 estimat...